Expertise in
29
conditions

Dr. Hassan Tahsildar

Oncology
Hassan Tahsildar, MD
1580 Commanche Ave, 
Green Bay, WI 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
29
conditions
Hassan Tahsildar, MD
1580 Commanche Ave, 
Green Bay, WI 

Overview

Hassan Tahsildar is an Oncologist practicing medicine in Green Bay, Wisconsin.

Dr. Tahsildar is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Small Lymphocytic Lymphoma (SLL), Small Cell Lung Cancer (SCLC), Lung Cancer, Chronic Lymphocytic Leukemia (CLL), and Endoscopy.

He is actively involved in clinical research, participating in 31 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in WI

Hospital Affiliations

Bellin Memorial Hospital
Bellin Health Oconto Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Children's Community Health
  • EPO
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Common Ground Healthcare
  • OTHER COMMERCIAL
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Icare Independent Care Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

Hassan Tahsildar, MD
1580 Commanche Ave, Green Bay, WI 54313

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

31 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: April 15, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Enrollment Status: Recruiting
Publish Date: April 14, 2026
Intervention Type: Radiation, Other
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Talazoparib
Study Phase: Phase 2
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: April 13, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
View 8 Less Clinical Trials
Similar Doctors
Expertise in
21
conditions
Dr. Ruth Warren
Oncology
Expertise in
21
conditions
Dr. Ruth Warren
Oncology

HSHS St. Mary's Hospital Medical Center

1726 Shawano Ave, 
Green Bay, WI 
 (3.3 miles away)
920-884-3135
Languages Spoken:
English
See accepted insurances

Ruth Warren is an Oncologist practicing medicine in Green Bay, Wisconsin. Dr. Warren is highly rated in 21 conditions, according to our data. Her clinical expertise encompasses Neuroendocrine Tumor, Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, Bone Marrow Aspiration, and Endoscopy.

Expertise in
30
conditions
Dr. Kevin Mortara
Hematology | Oncology
Expertise in
30
conditions
Dr. Kevin Mortara
Hematology | Oncology

Bellin Psychiatric Center Inc

1580 Commanche Ave, 
Green Bay, WI 
 (0.1 miles away)
920-435-8326
Languages Spoken:
English
See accepted insurances

Kevin Mortara is a Hematologist and an Oncologist practicing medicine in Green Bay, Wisconsin. Dr. Mortara is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Chronic Lymphocytic Leukemia (CLL), Paget Disease of the Breast, and Endoscopy.

Expertise in
39
conditions
Dr. Shannon Schmidt
Hematology | Oncology
Expertise in
39
conditions
Dr. Shannon Schmidt
Hematology | Oncology

Thedacare Regional Medical Center-Appleton Inc.

2500 E Capitol Dr, 
Appleton, WI 
 (18.9 miles away)
920-364-3600
Languages Spoken:
English
See accepted insurances

Shannon Schmidt is a Hematologist and an Oncologist practicing medicine in Appleton, Wisconsin. Dr. Schmidt is highly rated in 39 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, B-Cell Lymphoma, Angiosarcoma, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Hassan Tahsildar

How do I make an appointment with Dr. Hassan Tahsildar?

You can book an appointment with Dr. Hassan Tahsildar by calling their office at 920-435-8326. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Hassan Tahsildar a top-rated expert for Small Lymphocytic Lymphoma (SLL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Hassan Tahsildar is classified as an Distinguished expert for Small Lymphocytic Lymphoma (SLL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Hassan Tahsildar specialize in?

While Dr. Hassan Tahsildar is a Oncology, they have specific expertise in Small Lymphocytic Lymphoma (SLL), Small Cell Lung Cancer (SCLC), and Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Hassan Tahsildar accept my insurance?

Dr. Hassan Tahsildar accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 920-435-8326 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tahsildar's expertise for a condition
ConditionClose
    View All 23 Advanced Conditions
    View All 88 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile